PLIANT THERAPEUTICS, INC. - Common Stock, par value $0.0001 per share (PLRX)

Historical Holders from Q2 2020 to Q3 2025

Symbol
PLRX on Nasdaq
Type / Class
Equity / Common Stock, par value $0.0001 per share
Shares outstanding
61.7M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
50.4M
Holdings value
$74.6M
% of all portfolios
0%
Grand Portfolio weight change
+0%
Number of holders
97
Number of buys
33
Number of sells
-68
Average Value change %
0%
Average buys %
+0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of PLIANT THERAPEUTICS, INC. - Common Stock, par value $0.0001 per share (PLRX)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
TANG CAPITAL MANAGEMENT LLC 9.6% $9.2M 5.86M TANG CAPITAL MANAGEMENT, LLC 03 Mar 2025
Woodline Partners LP 7.3% $6.67M 4.5M Woodline Partners LP 30 Sep 2025
Point72 Asset Management, L.P. 6.7% $6.54M 4.09M Point72 Asset Management, L.P. 27 Aug 2025
MORGAN STANLEY 6.1% $5.27M 3.74M Morgan Stanley 30 Jun 2025
VANGUARD GROUP INC 4.89% $3.48M 3M The Vanguard Group 30 Jun 2025
Redmile Group, LLC 4.8% $4.55M 2.9M Redmile Group, LLC 31 Dec 2024
BlackRock, Inc. 3.4% $2.44M 2.1M BlackRock, Inc. 30 Jun 2025
FMR LLC 0.2% $207K 132K FMR LLC 28 Feb 2025
PRICE T ROWE ASSOCIATES INC /MD/ 0.1% $138K 87.7K T. Rowe Price Associates, Inc. 31 Mar 2025

Institutional Holders of PLIANT THERAPEUTICS, INC. - Common Stock, par value $0.0001 per share (PLRX)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 50.4M $74.6M +$1.54M $1.48 97
2025 Q2 51.5M $59.7M -$8.57M $1.16 112
2025 Q1 57.9M $78.1M -$217M $1.35 138
2024 Q4 64.8M $853M +$21.5M $13.17 158
2024 Q3 63.5M $714M -$5.61M $11.21 149
2024 Q2 63.9M $687M -$18.6M $10.75 141
2024 Q1 65.2M $971M +$41.5M $14.90 133
2023 Q4 62.7M $1.14B +$101M $18.11 133
2023 Q3 60.2M $1.04B +$29.4M $17.34 134
2023 Q2 58M $1.05B +$9.42M $18.12 141
2023 Q1 56.2M $1.5B +$313M $26.60 143
2022 Q4 44.7M $864M -$14.8M $19.33 123
2022 Q3 45.4M $948M +$327M $20.89 107
2022 Q2 30.1M $241M -$11.2M $8.01 81
2022 Q1 31.4M $220M +$4.11M $7.01 85
2021 Q4 30.9M $416M +$5.47M $13.50 81
2021 Q3 30.4M $513M -$14.9M $16.88 75
2021 Q2 30.7M $893M -$1.36M $29.12 80
2021 Q1 30.7M $1.21B +$88.1M $39.33 76
2020 Q4 28.5M $648M +$7.27M $22.72 57
2020 Q3 28.2M $636M +$17M $22.65 53
2020 Q2 26.9M $868M +$868M $32.46 36